Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-small Cell Lung Cancer

Nivolumab has become the standard second-line chemotherapy for non-small cell lung cancer. A 73-year-old man with stage IV non-small cell lung cancer received 6 cycles of chemotherapy with nab-paclitaxel/carboplatin/bevacizumab followed by 11 cycles of nab-paclitaxel/bevacizumab; however, treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Seigo, Tamiya, Akihiro, Taniguchi, Yoshihiko, Tanaka, Tsunehiro, Abe, Yuko, Isa, Shun-ichi, Tsuyuguchi, Kazunari, Suzuki, Katsuhiro, Atagi, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355398/
https://www.ncbi.nlm.nih.gov/pubmed/30101929
http://dx.doi.org/10.2169/internalmedicine.1195-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355398/
https://www.ncbi.nlm.nih.gov/pubmed/30101929
http://dx.doi.org/10.2169/internalmedicine.1195-18

Ejemplares similares